Cargando…

Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic

Extraovarian granulosa cell tumors are rare with very few cases of isolated retroperitoneal granulosa cell tumors reported in the literature. Granulosa cell tumors are notorious for late recurrences and patients should have long term oncologic follow up. We describe a case of recurrent granulosa cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Abedin, Yasmin, Madan, Upasana, Graham, Deena, Hellmann, Mira C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933688/
https://www.ncbi.nlm.nih.gov/pubmed/35313464
http://dx.doi.org/10.1016/j.gore.2022.100961
_version_ 1784671710227726336
author Abedin, Yasmin
Madan, Upasana
Graham, Deena
Hellmann, Mira C.
author_facet Abedin, Yasmin
Madan, Upasana
Graham, Deena
Hellmann, Mira C.
author_sort Abedin, Yasmin
collection PubMed
description Extraovarian granulosa cell tumors are rare with very few cases of isolated retroperitoneal granulosa cell tumors reported in the literature. Granulosa cell tumors are notorious for late recurrences and patients should have long term oncologic follow up. We describe a case of recurrent granulosa cell tumor of the retroperitoneum that originally presented as a renal mass, which has not been described before in the literature. Her management was delayed in part due to the COVID-19 Pandemic. Oncologists must be vigilant regarding the consequences of postponed care during this difficult time.
format Online
Article
Text
id pubmed-8933688
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89336882022-03-20 Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic Abedin, Yasmin Madan, Upasana Graham, Deena Hellmann, Mira C. Gynecol Oncol Rep Case Report Extraovarian granulosa cell tumors are rare with very few cases of isolated retroperitoneal granulosa cell tumors reported in the literature. Granulosa cell tumors are notorious for late recurrences and patients should have long term oncologic follow up. We describe a case of recurrent granulosa cell tumor of the retroperitoneum that originally presented as a renal mass, which has not been described before in the literature. Her management was delayed in part due to the COVID-19 Pandemic. Oncologists must be vigilant regarding the consequences of postponed care during this difficult time. Elsevier 2022-03-16 /pmc/articles/PMC8933688/ /pubmed/35313464 http://dx.doi.org/10.1016/j.gore.2022.100961 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Abedin, Yasmin
Madan, Upasana
Graham, Deena
Hellmann, Mira C.
Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic
title Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic
title_full Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic
title_fullStr Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic
title_full_unstemmed Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic
title_short Recurrent granulosa cell tumor of the retroperitoneum during the COVID-19 Pandemic
title_sort recurrent granulosa cell tumor of the retroperitoneum during the covid-19 pandemic
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933688/
https://www.ncbi.nlm.nih.gov/pubmed/35313464
http://dx.doi.org/10.1016/j.gore.2022.100961
work_keys_str_mv AT abedinyasmin recurrentgranulosacelltumoroftheretroperitoneumduringthecovid19pandemic
AT madanupasana recurrentgranulosacelltumoroftheretroperitoneumduringthecovid19pandemic
AT grahamdeena recurrentgranulosacelltumoroftheretroperitoneumduringthecovid19pandemic
AT hellmannmirac recurrentgranulosacelltumoroftheretroperitoneumduringthecovid19pandemic